Cilostazol for the treatment of depression in cardiac patients
- Conditions
- Major depressive disorder.Major depressive disorder, single episode
- Registration Number
- IRCT20090117001556N154
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Patients with coronary artery disease who underwent elective percutaneous coronary intervention or coronary-artery bypass grafting in the past three months due to angina pectoris or left ventricular dysfunction not associated with myocardial infarction.
Diagnosis of major depressive disorder based on DSM-V (score between 14 and 17).
Age between 40-60.
Patients who have taken antipsychotic drugs in the last year.
Diagnosis of other psychiatric disorders.
Electroconvulsive treatment in the last two months.
History of thyroid disease.
Inflammatory diseases, including autoimmune thyroiditis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, autoimmune hepatitis, migraine, Guillain-Barre syndrome, multiple sclerosis, and rheumatoid arthritis.
Being pregnant or breastfeeding.
History of allergy to Cilostazol.
Simultaneous need for antithrombin alpha, antithrombin III, argatroban, enoxaparin, apixaban, and other drugs with severe interaction with Cilostazol.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of depression. Timepoint: Weeks: 0-2-4-6. Method of measurement: By Hamilton Depression Rating Scale.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.